leisure time -WSS

leisure time

author：focus 2025-09-03 03:46:26 - browse：79519

WASHINGTON — A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry.

North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross.

Burr, now finishing his second term in the Senate, serves on committees with oversight of both the Food and Drug Administration and Medicare and Medicaid. He is also chairman of the Select Committee on Intelligence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Readout Newsletter: Illumina, CRISPR, Regeneron

focus

WSS

Texas board proposes rules on abortion law emergency exemption

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Biotech investment managers search for lucrative opportunities

Cancer, immunology, HIV research ensnared in fetal tissue politics

Mirador, a new biotech startup, launches with $400 million

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

hotspot

leisure time

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Peter Hotez and the public health issue of online harassment

'Patient friction coefficient' can gauge a clinical trial's patient burden

Apple is now the first public company to be valued at $3 trillion

What Kate Middleton's cancer revelation might teach the world

Psychedelics group wrestles with new pharma identity

CRISPR technology availability, affordability needs to be expanded

Cancer drug shortages should be causing more outrage

Biotech investment managers search for lucrative opportunities

focus

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Adam's Take: Intra

Biotech investment managers search for lucrative opportunities

U.K. officials, researchers try to ease path for bespoke genetic treatments

U.K. officials, researchers try to ease path for bespoke genetic treatments

Biotech investment managers search for lucrative opportunities

focus

focus

focus

leisure time